COCPライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:17):

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases...

Stats
本日の出来高	1 395.00
平均出来高	13 770.00
時価総額	15.48M
EPS	$0 ( 2024-04-03 )
次の収益日	( $-0.540 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.810
ATR14	$0.0310 (2.04%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-18	Frost Phillip Md Et Al	Buy	19 333	Stock Options (Right to Buy)
2023-07-18	Japour Anthony J	Buy	13 567	Stock Options (Right to Buy)
2023-07-18	Martin James Joseph	Buy	30 000	Stock Options (Right to Buy)
2023-07-18	Kornberg Roger D.	Buy	24 417	Stock Options (Right to Buy)
2023-07-18	Lee Sam	Buy	30 000	Stock Options (Right to Buy)

INSIDER POWER
100.00
Last 92 transactions
Buy: 58 610 813 \| Sell: 4 956 864

Cocrystal Pharma Inc 相関

10 最も正の相関
EGRX	0.876
SQQQ	0.873
FHTX	0.846
FEAM	0.845
AOSL	0.831
DLPN	0.825
ATEX	0.822
DRTS	0.812
ALLT	0.809
EMXC	0.807

10 最も負の相関
NYMTL	-0.892
NYMTM	-0.878
HLNE	-0.877
LFUS	-0.87
MAR	-0.87
NYMTN	-0.864
PTF	-0.863
OSIS	-0.856
SMH	-0.855
JSML	-0.854

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Cocrystal Pharma Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$1.39M (0.00 %)
EPS:	$-1.860

FY	2023
収益:	$0
総利益:	$1.39M (0.00 %)
EPS:	$-1.860

FY	2022
収益:	$0
総利益:	$-241 600 (0.00 %)
EPS:	$-4.77

FY	2021
収益:	$5.43M
総利益:	$0.00 (0.00 %)
EPS:	$-2.39

Financial Reports:

No articles found.

Cocrystal Pharma Inc

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.